Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

BIOSANTE PHARMACEUTICALS INC Form 8-K

August 16, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 16, 2004

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of

1-31812
mission File Number)

58-2301143 (I.R.S. Employer Identification

Incorporation)

(Commission File Number)

Number)

111 Barclay Boulevard Lincolnshire, Illinois

(Address of Principal Executive Offices)

60069 (Zip Code)

(847) 478-0500

(Registrant s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, If Changed Since Last Report)

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

Item 12. Results of Operations and Financial Condition.

On August 16, 2004, BioSante Pharmaceuticals, Inc. announced its financial results for the second quarter ended June 30, 2004. Attached to this Current Report on Form 8-K as Exhibit 99.1 is a copy of BioSante Pharmaceutical s press release in connection with the announcement. The information in this report is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference by any general statements by BioSante Pharmaceuticals, Inc. incorporating by reference this report or future filings into any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent BioSante Pharmaceuticals, Inc. specifically incorporates the information by reference.

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSANTE PHARMACEUTICALS, INC.

By: /s/ Phillip B. Donenberg
Phillip B. Donenberg
Chief Financial Officer, Treasurer and
Secretary

Dated: August 16, 2004